GLP-1 medications and mental health: what the neuropsychiatric evidence says about semaglutide and tirzepatide

Every few months a headline suggests that GLP-1 medications either cause psychiatric harm or cure addiction. Neither framing is accurate, and the real picture is both more nuanced and more useful. A 2025 pharmacovigilance study published in EClinicalMedicine looked specifically at the neuropsychiatric associations of Wegovy (semaglutide) and Zepbound (tirzepatide) in people with obesity -- with and without type 2 diabetes -- and the findings are worth walking through carefully (https://pubmed.ncbi.nlm.nih.gov/42373755/). At NoMi Beach Health, Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) reviews this kind of data because our patients ask us directly: will this medication affect how I feel mentally?

The short answer is: it might, and probably not in the direction you fear. But "probably" is not the same as "definitely," and the way we monitor matters.

What GLP-1 receptors are doing in the brain

Semaglutide and tirzepatide are best known for what they do in the gut and pancreas -- slowing gastric emptying, stimulating insulin release, and reducing glucagon. But GLP-1 receptors are also expressed in the brain, particularly in the hypothalamus, brainstem, and limbic system (https://pubmed.ncbi.nlm.nih.gov/38389048/). These are regions that regulate appetite, yes -- but also mood, reward, and impulse control.

Tirzepatide adds a twist. Where semaglutide targets only the GLP-1 receptor, tirzepatide (a dual GIP/GLP-1 agonist) also activates glucose-dependent insulinotropic polypeptide receptors, which have their own distribution in the central nervous system. Whether that dual mechanism shifts the neuropsychiatric profile is an active research question. What we know is that both drugs cross the blood-brain barrier to some degree, and their central effects are not incidental.

This is not alarming. It is actually why researchers have been interested in whether these drugs might help people with depression, cognitive decline, or substance use disorders. It does mean, however, that prescribing without a psychiatric history is incomplete prescribing.

What the 2025 pharmacovigilance study found

The EClinicalMedicine study drew on the FDA Adverse Event Reporting System (FAERS) and compared neuropsychiatric signals for semaglutide and tirzepatide across two populations: people with obesity alone, and people with obesity plus type 2 diabetes (https://pubmed.ncbi.nlm.nih.gov/42373755/). The results were not what many would expect.

For the outcomes that generate the most concern -- suicidality, self-harm, psychosis -- neither drug showed an elevated disproportionality signal compared to other weight-loss treatments. This aligns with a large 2023 population-based cohort study in the BMJ, which found no increased risk of suicidal ideation, depression, or anxiety in GLP-1 users, and actually observed lower rates of self-harm compared to controls on other medications (https://pubmed.ncbi.nlm.nih.gov/37963657/).

The more interesting finding was in positive neuropsychiatric associations. Both drugs were linked to signals suggesting reduced craving behavior and, in semaglutide users particularly, lower rates of certain substance-use-related events. This fits a growing body of preclinical and early clinical data suggesting GLP-1 receptor activation may dampen the reward signaling that drives compulsive eating, alcohol use, and possibly other addictive behaviors (https://pubmed.ncbi.nlm.nih.gov/36655442/).

There was also a difference between the two metabolic populations. People with obesity and type 2 diabetes showed a somewhat different signal profile than those with obesity alone. This likely reflects confounding from the profound metabolic normalization that comes with glucose control -- mood and energy shift when blood sugar stabilizes, and those shifts are not attributable to the drug alone in every case.

What this means for mood and anxiety specifically

Neither semaglutide nor tirzepatide appears to cause depression or anxiety in the general population. That is the most defensible summary of the current evidence, including a 2024 systematic review in Diabetes Care that looked at psychiatric adverse events across multiple GLP-1 studies and found no consistent causal signal (https://pubmed.ncbi.nlm.nih.gov/38237040/).

But here is the part that often gets left out of the headline: significant weight loss is itself a psychologically complex event. People who lose 15 to 20 percent of their body weight over 12 to 18 months -- as many SURMOUNT-1 participants did on tirzepatide (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) -- are undergoing a meaningful shift in body image, identity, appetite patterns, and social experience. Some people feel better than they have in years. Others feel unexpectedly flat, uncertain, or grieving the version of eating and socializing they are leaving behind.

That psychological experience is real and worth naming. We bring it up before people start, not after they call the office worried something is wrong.

Transient nausea and GI symptoms during dose titration can also affect mood indirectly -- it is hard to feel emotionally resilient when you are nauseated for six weeks. That is not a psychiatric adverse event; it is a side effect with a known time course that usually resolves with slower titration.

The addiction signal: promising, not proven

The reward-pathway angle deserves a measured paragraph of its own, because the clinical curiosity around it is legitimate and growing.

GLP-1 receptors in the ventral tegmental area and nucleus accumbens are involved in dopamine-mediated reward signaling (https://pubmed.ncbi.nlm.nih.gov/36655442/). In animal models, GLP-1 agonists reduce voluntary alcohol intake, decrease cocaine seeking, and blunt nicotine reward. Human observational data have found lower rates of alcohol use disorder events in GLP-1 users compared to other drug classes. The 2025 pharmacovigilance study adds to this picture.

None of this means we prescribe semaglutide or tirzepatide as addiction treatment. The evidence base for that indication does not yet exist in the form of randomized controlled trials with clinical endpoints. What it does mean is that if you are on one of these medications and you notice that your relationship with alcohol or food cravings has shifted, that is consistent with the pharmacology -- and worth discussing.

For a deeper look at how GLP-1 medications compare on efficacy and tolerability more broadly, our GLP-1 weight loss guide covers that ground in detail.

How diabetes status changes the picture

The FAERS data suggest that the neuropsychiatric signal is not identical across metabolic phenotypes. People with type 2 diabetes who start a GLP-1 medication are often experiencing rapid normalization of chronically elevated blood glucose. That normalization can produce its own mood and cognitive effects -- sometimes positive (reduced brain fog, better energy), sometimes disorienting (the body recalibrating to a new metabolic set point).

This is why we ask about prior glycemic history, baseline HbA1c, and current diabetes management before prescribing in someone with type 2 diabetes. It is also why our follow-up schedule in the first 12 weeks is more frequent than most primary care practices use. The SELECT trial for semaglutide (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563) and SURMOUNT-1 for tirzepatide both enrolled people across the spectrum of metabolic disease, but subgroup neuropsychiatric analyses are limited. The 2025 study helps fill that gap, and its findings inform how we structure our monitoring.

If you are interested in how long-term outcomes compare across weight loss interventions, our 1-year outcomes post covers the data for semaglutide, tirzepatide, and sleeve gastrectomy side by side.

What we check before and during treatment

When Dr. Harris evaluates someone for a GLP-1 medication, psychiatric and behavioral history is part of that conversation -- not an afterthought. Here is what that looks like in practice:

Before starting, we ask about any personal or family history of mood disorders, eating disorders, or substance use. We note current psychiatric medications, because several have metabolic interactions worth knowing. We discuss what rapid weight loss can feel like emotionally, because surprises are harder to manage than things you have been told to expect.

During dose titration, we watch for mood changes, appetite disturbances that go beyond expected GI side effects, and any shift in substance use behavior. We communicate through our portal and are reachable between visits -- a follow-up message at week 6 is part of the protocol, not an exception.

At quarterly reviews, we revisit both metabolic markers and subjective wellbeing. Hemoglobin A1c, weight, and hematocrit get checked. So does how you are actually doing.

We also do not operate in silos. If you are working with a therapist or psychiatrist, we coordinate. GLP-1 therapy and behavioral health support are not competing -- they work better together, especially when weight loss is significant and sustained.

For those managing ADHD alongside these questions -- which comes up more often than you might expect in people seeking weight management support -- our ADHD evaluation post covers what a proper workup looks like.

The honest summary

Semaglutide and tirzepatide do not appear to cause depression, suicidality, or psychosis based on current pharmacovigilance and cohort data. The available evidence actually leans in the opposite direction for several neuropsychiatric outcomes. The reward-pathway and addiction findings are biologically plausible and intriguing, but not yet an established clinical indication. Having type 2 diabetes alongside obesity adds complexity to interpreting neuropsychiatric changes during treatment.

None of this is a reason to avoid these medications. It is a reason to prescribe them carefully, monitor thoughtfully, and have the honest conversation about what the psychological experience of significant weight loss actually involves.

That is what we do.

---

If you are considering semaglutide or tirzepatide and want a clinician who will look at your full picture -- metabolic, behavioral, and psychiatric -- book a medical weight loss visit at NoMi Beach Health or call us at (786) 744-5152. We will draw the right labs, ask the right questions, and tell you what the evidence actually supports.